Preclinical Activity of Selinexor, an Inhibitor of XPO1, in Sarcoma

Oncotarget - United States
doi 10.18632/oncotarget.7667
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Impact Journals, LLC

Related search

Selinexor, a First-In-Class XPO1 Inhibitor, Is Efficacious and Tolerable in Patients With Myelodysplastic Syndromes Refractory to Hypomethylating Agents

Blood
BiochemistryImmunologyCell BiologyHematology
2018English

XPO1 Inhibition by Selinexor Induces Potent Cytotoxicity Against High Grade Bladder Malignancies

Oncotarget
Oncology
2018English

Preclinical Evaluation of Biomarkers Associated With Antitumor Activity of MELK Inhibitor

Oncotarget
Oncology
2016English

Activity of PXD101, a Histone Deacetylase Inhibitor, in Preclinical Ovarian Cancer Studies

Molecular Cancer Therapeutics
Cancer ResearchOncology
2006English

Preclinical Antitumor Activity of SST0116CL1: A Novel Heat Shock Protein 90 Inhibitor

International Journal of Oncology
Cancer ResearchOncology
2014English

Preclinical Evaluation of Antitumor Activity of the Proteasome Inhibitor MLN2238 (Ixazomib) in Hepatocellular Carcinoma Cells

Cell Death and Disease
Molecular NeuroscienceImmunologyCell BiologyCancer ResearchCellularMedicine
2018English

Antitumor Activity of the Polo-Like Kinase Inhibitor, TAK-960, Against Preclinical Models of Colorectal Cancer

BMC Cancer
Cancer ResearchOncologyGenetics
2018English

Preclinical Test of Dacomitinib, an Irreversible EGFR Inhibitor, Confirms Its Effectiveness for Glioblastoma

Molecular Cancer Therapeutics
Cancer ResearchOncology
2015English

A Novel PI3K Inhibitor PIK-C98 Displays Potent Preclinical Activity Against Multiple Myeloma

Oncotarget
Oncology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy